mRNA

This collection of insights, produced through a partnership between

, and Bioprocess Online, highlights strategies and guidance to ensure reliable biomanufacturing capacity and supply chains for the delivery of health technologies like vaccines, even during crisis conditions.

In this webinar, join industry experts to learn about strategies to accelerate mRNA therapies and enable scalability and process efficiency from preclinical to commercial.

Purification efficiency evaluated endotoxin and host cell protein (HCP) clearance, plasmid yield, potential interference of the detergents with analytical in-process control assays, and overall process compatibility, and this comprehensive screening approach provides valuable insights to intensified plasmids production.

The covid-19 pandemic forced rapid vaccine development and market approval, shortening a process that normally takes years to just a few months. This experience raises a tantalising question: can such speed be sustained for other treatments?

Check out this article where

‘s Eva Schaefer, Director of Supply Robustness, and Tom Elich, MSAT Manager, discuss how industry collaboration has never been more important.

Collaboration between biomanufacturers and CDMOs often experiences challenges with data sharing. This presentation highlights the management of heterogenous and asynchronous data and how a data integration platform can improve project lifecycle data management, and collaborative data sharing.

In this On-Demand version of the presentations, key opinion leaders from

, Hileman Laboratories Singapore, Baylor College of Medicine or Biofarma, provide a fascinating story of the behind of the scenes development of the recent pandemic and how long-term collaboration to optimize a neglected tropical disease vaccine platform transformed into the COVID-19 vaccine candidates.

mRNA technology has proven to enable rapid drug development. mRNA is an attractive modality to work with because of its relative simplicity compared to other biologics; it is wholly synthetic and does not require cellular materials.

mRNA technology offers many opportunities but the development and manufacturing of mRNA-based vaccines and therapeutics present a number of challenges. Learn more about the opportunities of the mRNA technology and how to overcome drug development and manufacturing challenges to bring your mRNA-based therapies to market in this first webinar.

This whitepaper describes the development and use of a cost model encompassing capital, labor, materials, consumables, and other costs, which are five key parameters of manufacturing for a variety of vaccine modalities: vaccines which use inactivated and attenuated viruses, protein subunit vaccines, virus-like particles (VLP) vaccines, Viral vector vaccines, and mRNA vaccines.